No Data
No Data
Changes in Hong Kong stocks | The collective decline in pharmaceutical stocks will improve the quality and expansion of pharmaceutical procurement, which is expected to form a national alliance for procurement
Pharmaceutical stocks fell collectively today. As of press release, Luye Pharmaceuticals (02186) fell 7.72% to HK$2.75; Kaituo Pharmaceutical-B (09939) fell 7.35% to HK$1.26; Zhongsheng Pharmaceuticals (01177) fell 5.75% to HK$2.95; and Cinda Biotech (01801) fell 4.61% to HK$38.3.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Luye Pharmaceuticals (02186.HK) gains 3.569,500 shares from UBS Group AG
Glonghui, May 9 | According to the latest equity disclosure data on the Stock Exchange, on May 2, 2024, Luye Pharmaceutical (02186.HK) received UBS Group AG's good holdings of 3.569,500 shares at an average price of HK$2.9389 per share on the market, involving approximately HK$10.49 million. After the increase in holdings, UBS Group AG's latest number of good positions was 452,878,777 shares, and the holding ratio increased from 11.94% to 12.04%.
綠葉製藥:年報 2023
Luye Pharma Group Ltd. (HKG:2186) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 17.8x Luye Pharma Group Ltd. (HKG:2186) may be sending very bearish signals at the moment, given that almost half of all companies in Hong Kong have P/E ra
[Broker Focus] Tianfeng Securities maintains Luye Pharmaceutical's (02186) “buy” rating, indicating that the main types of core business have large market space
Jinwu Financial News | According to Tianfeng Securities Research Report, Luye Pharmaceutical (02186) announced 2023 results: overall operating revenue of 6.14 billion yuan in 2023, up 2.7% year on year, product sales revenue of 5.63 billion yuan, up 11.2% year on year, and net profit to mother of 533 million yuan, down 11.9% year on year. The decline in net profit is mainly due to a decrease in the share of authorized revenue. The company's overall performance was in line with expectations. The bank mentioned that subsequent sales volume of core products and progress in the research pipeline are worth looking forward to, and there is plenty of room for reasonable valuation. According to this bank, considering the outstanding advantages of the company's new products, there will be many
No Data